TRYP Therapeutics Inc. (C:TRYP)

Business Focus: Biotechnology & Medical Research (NEC)

Get the company report for the most recent outlook updated daily

Apr 24, 2024 06:00 am ET

Tryp Therapeutics Provides Update on Plan of Arrangement With Exopharm Limited and Announces Voluntary Trading Halt

KELOWNA, BC / ACCESSWIRE / April 24, 2024 / Tryp Therapeutics, Inc. ("Tryp" or the "Company") (CSE:TRYP)(OTCQB:TRYPF) is pleased to announce that the shareholders of Exopharm Limited ACN 163 765 991 ("Exopharm") have approved the previously announced plan of arrangement (the "Arrangement") between the parties.

Mar 12, 2024 06:00 am ET

Tryp Therapeutics Announces 99.92% Votes Cast by Shareholders in Favor of Arrangement Agreement at Annual General and Special Meeting of Securityholders, and Receipt of Final Order

KELOWNA, BC / ACCESSWIRE / March 12, 2024 / Tryp Therapeutics, Inc. ("Tryp" or the "Company") (CSE:TRYP)(OTCQB:TRYPF) is pleased to announce that the Company's securityholders overwhelmingly approved the previously announced arrangement (the "Arrangement") involving the Company and Exopharm Limited CAN 163 765 991 at the Company's annual general and special meeting of securityholders (the "Meeting") held on March 8, 2024. The Company is also pleased to a

Mar 05, 2024 01:54 pm ET

CSE Bulletin: Reinstatement - Tryp Therapeutics Inc. (TRYP)

Toronto, Ontario--(Newsfile Corp. - le 5 mars/March 2024) - Effective immediately, Tryp Therapeutics Inc. will be reinstated for trading.

Mar 05, 2024 12:47 pm ET

Canadian Investment Regulatory Organization Trade Resumption - TRYP

VANCOUVER, BC, March 5, 2024 /CNW/ - Trading resumes in:

Feb 08, 2024 04:00 pm ET

Tryp Therapeutics Obtains Interim Order for Plan of Arrangement and Provides Details of Shareholder Meeting

KELOWNA, BC / ACCESSWIRE / February 8, 2024 / Tryp Therapeutics, Inc. ("Tryp" or the "Company") (CSE:TRYP)(OTCQB:TRYPF), a pioneering clinical-stage biotechnology company focused on developing intravenous-infused psilocin (the active metabolite of psilocybin) for diseases with high unmet medical needs, today announced that further to its press releases of December 11, 2023 and January 26, 2024, Tryp has obtained an interim order (the "Interim Order") of the Supreme Court of Britis

Feb 05, 2024 07:10 am ET

Canadian Investment Regulatory Organization Trading Halt - TRYP

VANCOUVER, BC, Feb. 5, 2024 /CNW/ - The following issues have been halted by CIRO:

Jan 26, 2024 06:00 am ET

Tryp Therapeutics and Exopharm Limited Secure Pivotal 2 Cent Waiver From ASX

KELOWNA, BC / ACCESSWIRE / January 26, 2024 / Tryp Therapeutics, Inc. ("Tryp" or the "Company") (CSE:TRYP)(OTCQB:TRYPF), a pioneering clinical-stage biotechnology company focused on developing intravenous-infused psilocin (the active metabolite of psilocybin) for diseases with high unmet medical needs, today announced that in a strategic move to foster a robust market for their combined entity, Tryp and Exopharm Limited have been granted a pivotal 2 cent waiver by the Australian Securities

Jan 08, 2024 07:00 am ET

Tryp Therapeutics Announces Significant Milestone in Its Clinical Trial Program for Trp-8803 (IV-infused Psilocin)

KELOWNA BC / ACCESSWIRE / January 8, 2024 / Tryp Therapeutics, Inc. ("Tryp" or the "Company") (CSE:TRYP)(OTCQB:TRYPF), a pioneering clinical-stage biotechnology company focused on developing intravenous-infused psilocin (the active metabolite of psilocybin) for diseases with high unmet medical needs,today announced a significant milestone in its clinical trial program for TRP-8803 (IV-infused psilocin). The Company has received approval from the Human Research Ethics Committee (HREC) in Aus

Jan 04, 2024 06:00 am ET

Tryp Therapeutics Announces First Patient Dosed in Phase 2a Clinical Trial for the Treatment of Fibromyalgia at The University of Michigan

KELOWNA, BC / ACCESSWIRE / January 4, 2024 / Tryp Therapeutics Inc. ("Tryp" or the "Company") (CSE:TRYP), a clinical-stage biotechnology company focused on developing intravenous-infused psilocin (the active metabolite of psilocybin) for diseases with high unmet medical needs,is pleased to announce that the first patient has been dosed in a Phase 2a clinical trial being conducted by the University of Michigan in a collaboration with Tryp Therapeutics. The clinical trial is evaluating Tryp's TRP-8802 in pati

Dec 11, 2023 04:00 am ET

Tryp Therapeutics Inc. Announces Signing of Definitive Agreement with Exopharm Limited

KELOWNA, BC / ACCESSWIRE / December 11, 2023 / Tryp Therapeutics Inc. ("Tryp" or the "Company") (CSE:TRYP), a clinical-stage biotechnology company focused on developing intravenous-infused psilocin (the active metabolite of psilocybin) for diseases with high unmet medical needs, is pleased to announce that the Company has entered into an arrangement agreement (the "Arrangement Agreement") with Exopharm Limited ACN 163 765 991 ("Exopharm" or the "

Nov 20, 2023 06:00 am ET

Tryp Therapeutics Announces Closing of Oversubscribed Private Placement of Unsecured Convertible Notes for Gross Proceeds of AUD$3,215,000

KELOWNA, BC / ACCESSWIRE / November 20, 2023 / Tryp Therapeutics Inc. ("Tryp" or the "Company") (CSE:TRYP), a clinical-stage biotechnology company focused on developing intravenous-infused psilocin (the active metabolite of psilocybin) for diseases with high unmet medical needs,is pleased to announce that it has closed its previously announced private placement (the "PrivatePlacement") of unsecured convertible notes (the "Notes") for aggregate gross proc

Nov 02, 2023 06:00 am ET

Tryp Therapeutics Inc. Announces Private Placement of Unsecured Convertible Notes for Gross Proceeds of AUD$3.0 Million

KELOWNA, BC / ACCESSWIRE / November 2, 2023 / Tryp Therapeutics, Inc. ("Tryp" or the "Company") (CSE:TRYP), a clinical-stage biotechnology company focused on developing intravenous-infused psilocin (the active metabolite of psilocybin) for diseases with high unmet medical needs, is pleased to announce a private placement (the "Private Placement") of unsecured convertible notes (the "Notes") for an aggregate principal amount of up to AUD$

Oct 11, 2023 04:30 pm ET

Tryp Therapeutics Announces Closing of Private Placement of Unsecured Convertible Debentures for Gross Proceeds of AUD$175,000

KELOWNA, BC / ACCESSWIRE / October 11, 2023 / Tryp Therapeutics Inc. ("Tryp" or the "Company") (CSE:TRYP), a clinical-stage biotechnology company focused on developing intravenous-infused psilocin (the active metabolite of psilocybin) for diseases with high unmet medical needs,is pleased to announce that it has closed its previously announced private placement (the "Private Placement") of unsecured convertible debentures (the "Debentures"

Aug 03, 2023 06:00 am ET

Tryp Therapeutics Announces Jason Carroll as New Chief Executive Officer

KELOWNA, BC / ACCESSWIRE / August 3, 2023 / Tryp Therapeutics Inc. (CSE:TRYP)(OTCQB:TRYPF) ("Tryp" or the "Company"), a clinical-stage biotechnology company dedicated to developing intravenous-infused psilocin (the active metabolite of psilocybin) for diseases with high unmet medical needs, is pleased to announce the appointment of Australia-based Jason Carroll as the Company's new Chief Executive Officer, beginning October 1, 2023.

Aug 02, 2023 06:00 am ET

With Great Sadness Tryp Announces the Passing of David Tousley, Director

KELOWNA, BC / ACCESSWIRE / August 2, 2023 / Tryp Therapeutics, Inc. (CSE:TRYP)(OTCQB:TRYPF) ("Tryp" or the "Company"), announces with deep regret the passing of Mr. David Tousley, Director of Tryp and Chair of Tryp's Audit Committee. Dave was a highly experienced director who provided the Board with consistent, sage advice. His input was always well-reasoned and practical on issues brought to the Board. He worked tirelessly on behalf of TRYP and was always available for discussions on many detailed matters. We will m

Jul 13, 2023 06:00 am ET

Tryp Therapeutics Receives Confirmation From FDA To Proceed With Phase 2A Clinical Trial in Patients With IBS at Massachusetts General Hospital

KELOWNA, BC / ACCESSWIRE / July 13, 2023 / Tryp Therapeutics, Inc. (CSE:TRYP)(OTCQB:TRYPF) ("Tryp" or the "Company"), a clinical-stage biotechnology company focused on developing intravenous-infused psilocin (the active metabolite of psilocybin) for diseases with high unmet medical needs, today announced it has received confirmation from the U.S. Food and Drug Administration ("FDA") that its review of Tryp's Investigational New Drug ("IND") #163,994 is complete and that the Company may proceed wit

May 24, 2023 06:00 am ET

Tryp Therapeutics Submits Investigational New Drug (IND) Application to US FDA for Planned Phase 2a Clinical Trial in Patients With IBS at Massachusetts General Hospital

KELOWNA, BC / ACCESSWIRE / May 24, 2023 / Tryp Therapeutics, Inc. (CSE:TRYP)(OTCQB:TRYPF) ("Tryp" or the "Company"), a clinical-stage biotechnology company focused on developing intravenous-infused psilocin (the active metabolite of psilocybin) for diseases with high unmet medical needs, today announced it has submitted an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) for its planned Phase 2a clinical trial investigating the effects of psilocybin-assisted psychoth

May 22, 2023 11:54 am ET

Tryp Therapeutics discusses unique approach to psychedelic treatment study of binge eating

Tryp Therapeutics CEO James Gilligan joins Natalie Stoberman from the Proactive studio to share how the company is developing psychedelic-assisted therapy in treating various disorders such as binge eating and IBS.

Apr 27, 2023 06:00 am ET

Tryp Therapeutics Announces Closing of Oversubscribed Private Placement of Secured Convertible Debentures for Gross Proceeds of AUD$2,400,000

KELOWNA, BC / ACCESSWIRE / April 27, 2023 / Tryp Therapeutics Inc. ("Tryp" or the "Company") (CSE:TRYP), a clinical-stage biotechnology company focused on developing intravenous-infused psilocin (the active metabolite of psilocybin) for diseases with high unmet medical needs,is pleased to announce that it has closed its previously announced private placement (the "Private Placement") of secured convertible debentures (the "Debentures") f

Apr 12, 2023 04:00 pm ET

Tryp Therapeutics Announces Private Placement of Secured Convertible Debentures for Gross Proceeds of a Minimum of AUD$2,000,000

KELOWNA, BC / ACCESSWIRE / April 12, 2023 / Tryp Therapeutics Inc. ("Tryp" or the "Company") (CSE:TRYP), a clinical-stage biotechnology company focused on developing intravenous-infused psilocin (the active metabolite of psilocybin) for diseases with high unmet medical needs,is pleased to announce a private placement (the "Private Placement") for a minimum aggregate principal amount of AUD$2.0 million, with the ability to accept oversubscriptions

Apr 04, 2023 06:00 am ET

Tryp Therapeutics Completes Psychotherapy Training for Planned Phase 2a Clinical Trial at Massachusetts General Hospital

KELOWNA, BC / ACCESSWIRE / April 4, 2023 / Tryp Therapeutics, Inc. (CSE:TRYP)(OTCQB:TRYPF) ("Tryp" or the "Company"), a clinical-stage biotechnology company focused on developing intravenous-infused psilocin (the active metabolite of psilocybin) for diseases with high unmet medical needs, today announced it has completed the training of psychotherapists for its planned Phase 2a clinical trial investigating the effects of psilocybin-assisted psychotherapy in the treatment of patients aged 21+ suffering from Irr

Jan 05, 2023 07:00 am ET

Tryp Therapeutics Announces Interim Results for Its Phase II Clinical Trial for the Treatment of Binge Eating Disorder With Psilocybin-Assisted Psychotherapy

Interim data analysis supports the potential effectiveness of psilocybin-assisted psychotherapy for the treatment of Binge Eating Disorder

Jan 03, 2023 07:00 am ET

Tryp Therapeutics and Massachusetts General Hospital Sign Letter of Intent for Clinical Study Investigating the Use of Psilocybin-Assisted Psychotherapy for the Treatment of Patients Suffering From Ir

KELOWNA, BC / ACCESSWIRE / January 3, 2023 / Tryp Therapeutics, Inc. (CSE:TRYP) (OTCQB:TRYPF) ("Tryp" or the "Company"), a clinical-stage biotechnology company focused on developing intravenous-infused psilocin (the active metabolite of psilocybin) for diseases with high unmet medical needs, today announced the signing of a letter of intent with Massachusetts General Hospital (MGH), the largest teaching hospital of Harvard Medical School, to fund and conduct a Phase 2a clinical trial

Dec 21, 2022 10:50 am ET

Tryp Therapeutics to Present at Biotech Showcase on Monday, January 9, 2023

Tryp Therapeutics, Inc. (CSE: TRYP) (OTCQB: TRYPF), a clinical-stage biotechnology company focused on developing intravenous-infused psilocin (the active metabolite of psilocybin) for diseases with high unmet medical needs, today announced that the...

Dec 16, 2022 08:35 am ET

KCSA Mental Health Virtual Investor Conference: Presentations Now Available for Online Viewing

Virtual Investor Conferences, the leading proprietary investor conference series, in partnership with KCSA Strategic Communications (“KCSA”), today announced the presentations from its KCSA Mental Health Virtual Investor Conference held on December...

Dec 13, 2022 04:05 pm ET

Tryp Therapeutics Announces Fiscal Year 2022 Financial Results and Reports Corporate Highlights

Dec 13, 2022 08:35 am ET

KCSA Mental Health Virtual Investor Conference Agenda Announced for December 15th

Virtual Investor Conferences, the leading proprietary investor conference series, in partnership with KCSA Strategic Communications (“KCSA”), today announced the agenda for the upcoming KCSA Mental Health Virtual Investor Conference to be held on...

Dec 12, 2022 07:00 am ET

Tryp Therapeutics to Webcast Live at VirtualInvestorConferences.com on Thursday, December 15

Nov 10, 2022 08:30 am ET

Tryp Therapeutics Announces Poster Presentations on the Reduction of Chronic Pain in a Rodent Model with Psilocybin and Intravenous Psilocybin Alters Brain Network Dynamics in Rats at the 2022 Society

Tryp Therapeutics, Inc. (CSE: TRYP) (OTCQB: TRYPF) ("Tryp" or the "Company"), a clinical-stage biotechnology company focused on developing psilocybin-based compounds for diseases with unmet medical needs, today announced that the Company’s...

Oct 03, 2022 04:10 pm ET

Tryp Therapeutics Announces Publication of International PCT Patent Application for the Intravenous Administration of Psilocin and Psilocybin

Sep 26, 2022 08:30 am ET

Tryp Therapeutics Strengthens Intellectual Property Portfolio with Provisional Patent Applications for Fibromyalgia Treatment and for Crystalline Forms of TRP-8803

Sep 19, 2022 08:30 am ET

Tryp Therapeutics Appoints Jim O’Neill as Chief Financial Officer

Tryp Therapeutics Inc. (CSE: TRYP) ("Tryp" or the "Company"), a clinical-stage biotechnology company focused on developing psilocybin-based compounds for diseases with unmet medical needs, today announced that it has expanded its leadership team...

Sep 13, 2022 09:06 am ET

Tryp Therapeutics Retains IMS Investor Relations

Jul 08, 2022 06:00 pm ET

TRYP THERAPEUTICS INC. ANNOUNCES CLOSING OF THIRD TRANCHE OF PRIVATE PLACEMENT

SAN DIEGO, July 8, 2022 /CNW/ -- Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF) ("Tryp" or the "Company"), a clinical-stage biotechnology company focused on developing psilocybin-based compounds for diseases with unmet medical needs, announces that it has completed a third tranche of its private placement (the "Private Placement") previously announced on February 4, 2022, February 17, 2022 and April 22, 2022 for aggregate gross proceeds of $150,000 through the issuance of 1,000,000 Units of the Company (the "Units") at a price of $0.15 per Unit. Each Unit is comprised of one (1) Common Share a

Jun 23, 2022 08:00 am ET

Tryp Therapeutics Appoints New Chief Operating Officer

Sid Taubenfeld with Extensive Experience in the Financial Markets and as a Biotech Executive Joins Tryp as Company Prepares to Expand Patient Access to Psilocybin-Based Treatments

Jun 09, 2022 08:00 am ET

TRYP THERAPEUTICS ANNOUNCES RESULTS OF FIRST PATIENT DOSED IN ITS PHASE II CLINICAL TRIAL FOR THE TREATMENT OF BINGE EATING DISORDER

Initial data readout supports the potential effectiveness of psilocybin and psilocybin-related compounds for the treatment of Binge Eating Disorder

May 25, 2022 08:00 am ET

Tryp Therapeutics Strengthens Board of Directors with Appointment of Chris Ntoumenopoulos as Independent Director

Industry leader Chris Ntoumenopoulos to support biotech Company's mission to advance the delivery of psychedelic medicines

Apr 28, 2022 08:00 am ET

TRYP THERAPEUTICS DOSES FIRST PATIENT IN PHASE II PSILOCYBIN-ASSISTED THERAPY CLINICAL TRIAL

Phase II trial to determine efficacy of psilocybin in combination with psychotherapy for potential treatment of Binge Eating Disorder

Apr 22, 2022 05:46 pm ET

TRYP THERAPEUTICS INC. Announces Amendment to Terms of Private Placement and Closing of $3,000,000 Second Tranche

SAN DIEGO, CALIFORNIA – TheNewswire - April 22, 2022 – Tryp Therapeutics (CSE:TRYP) (OTC:TRYPF) (“Tryp” or the “Company"), a pharmaceutical company focused on developing psilocybin-based compounds for diseases with unmet medical needs, announces that it has amended the terms of its private placement (the “Private Placement”) previously announced on February 4, 2022 and February 17, 2022. The Company also announces the closing of a second tranche of the Private Placement for aggregate gross proceeds of $3,000,000 and the settlement of certain accounts payable for consulting services through t

Mar 23, 2022 08:00 am ET

Tryp Therapeutics Initiates Enrollment for Binge Eating Disorder Study in Partnership with University of Florida

Phase 2 study is the first approved by the FDA and DEA to test psychedelic therapies in the area of binge eating disorders

Feb 22, 2022 06:30 am ET

TRYP THERAPEUTICS INC. ANNOUNCES BOARD CHANGES AND CLOSING OF FIRST TRANCHE OF PRIVATE PLACEMENT

Recognized industry leader brings deep finance and operational experience to Tryp board

Feb 17, 2022 09:18 pm ET

TRYP THERAPEUTICS INC. ANNOUNCES UPSIZING OF PREVIOUSLY ANNOUNCED PRIVATE PLACEMENT

REVISED DEAL INCLUDES INCREASE IN PREMIUM SHARE PRICE TO $0.20 PER SHARE WITHOUT WARRANTS

Feb 04, 2022 08:30 am ET

Tryp Therapeutics Announces $2,000,000 Financing and Changes in Management, Board of Directors

SAN DIEGO – TheNewswire - February 4, 2022 – Tryp Therapeutics (CSE:TRYP) (CNSX:TRYP.CN) (OTC:TRYPF) ("Tryp” or the “Company"), a pharmaceutical company focused on developing psilocybin-based compounds for diseases with unmet medical needs, is pleased to announce a non-brokered private placement (the "Placement") to its co-Founder and Executive Director, William J. Garner, M.D. The Placement consists of 11,111,111 million units (the "Units") at a price of $0.18 per Unit, to raise gross proceeds of approximately $2.0 million. Each Unit consists of one Common Share (each, a "Common Share") and

Jan 05, 2022 06:00 am ET

Tryp Therapeutics to Participate in Healthcare Conferences in January 2022

SAN DIEGO, Jan. 5, 2022 /PRNewswire/ -- Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF) ("Tryp" or the "Company"), a pharmaceutical company focused on developing psilocybin-based compounds for diseases with unmet medical needs, announced today that it will present next week at the H.C. Wainwright Bioconnect Conference and the Biotech Showcase.

Dec 23, 2021 06:05 am ET

Tryp Therapeutics Announces Advancement of Phase 2a Clinical Trial in Binge Eating Disorder

SAN DIEGO, Dec. 23, 2021 /PRNewswire/ -- Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF) ("Tryp" or the "Company"), a pharmaceutical company focused on developing psilocybin-based compounds for diseases with unmet medical needs, announced today the receipt of correspondence from the U.S. Food and Drug Administration (FDA) affirming the Company's ability to proceed with a Phase 2a clinical trial evaluating the use of synthetic psilocybin for binge eating disorder.

Dec 22, 2021 12:15 pm ET

Tryp Therapeutics Receives Confirmation from FDA to Proceed with Phase 2a Study in Fibromyalgia

SAN DIEGO, Dec. 2, 2021 /PRNewswire/ -- Tryp Therapeutics (CSE:TRYP) (OTCQB:TRYPF) ("Tryp" or the "Company"), a pharmaceutical company focused on developing psilocybin-based compounds for diseases with unmet medical needs, announced today that it has received confirmation from the U.S. Food and Drug Administration ("FDA") that its review of Tryp's Investigational New Drug ("IND") application is complete and that the Company may proceed with its clinical study in fibromyalgia.

Dec 22, 2021 08:00 am ET

Tryp Therapeutics Announces Fiscal Year 2021 Financial Results and Reports on Corporate Highlights

SAN DIEGO, Dec. 22, 2021 /PRNewswire/ -- Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF) ("Tryp" or the "Company"), a pharmaceutical company focused on developing psilocybin-based compounds for diseases with unmet medical needs, announced today the filing of its audited financial statements for the fiscal year ending August 31, 2021 and reported on corporate highlights from 2021. Complete financial statements along with related management discussion and analysis can be found in the System for Electronic Document Analysis and Retrieval, the electronic filing system for the disclosure documents

Dec 03, 2021 06:05 am ET

Tryp Therapeutics to Present at the H.C. Wainwright Psychedelics Conference on December 6, 2021

SAN DIEGO, Dec. 3, 2021 /PRNewswire/ -- Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF) ("Tryp or the "Company"), a pharmaceutical company focused on developing psilocybin-based compounds for diseases with unmet medical needs, announced today that it will present at the 2nd Annual H.C. Wainwright Psychedelics Conference.

Dec 03, 2021 06:05 am ET

Tryp Therapeutics to Present at the H.C. Wainwright Psychedelics Conference on December 6, 2021

SAN DIEGO, Dec. 3, 2021 /CNW/ -- Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF) ("Tryp or the "Company"), a pharmaceutical company focused on developing psilocybin-based compounds for diseases with unmet medical needs, announced today that it will present at the 2nd Annual H.C. Wainwright Psychedelics Conference.

Nov 04, 2021 07:05 am ET

Tryp Therapeutics to Participate in Wonderland: Miami on November 8

San Diego, California--(Newsfile Corp. - November 4, 2021) - - Nov. 4, 2021 - Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF) ("Tryp" or the "Company"), a pharmaceutical company focused on developing psilocybin-based compounds for diseases with unmet medical needs, announced today that the Company will participate in Wonderland: Miami, presented by Microdose, on November 8, 2021.

Nov 02, 2021 07:05 am ET

Tryp Therapeutics Submits IND Application for Phase 2a Clinical Trial in Fibromyalgia

San Diego, California--(Newsfile Corp. - November 2, 2021) - Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF) ("Tryp" or the "Company"), a pharmaceutical company focused on developing psilocybin-based compounds for diseases with unmet medical needs, announced today that it has submitted an Investigational New Drug ("IND") application to the U.S. Food and Drug Administration ("FDA") to evaluate its clinical candidate, TRP-8802, in a Phase 2a clinical trial that investigates safety and preliminary effectiveness of psilocybin-assisted therapy among patients with fibromyalgia in collaboration with the University of Michigan.

Oct 26, 2021 07:05 am ET

Tryp Therapeutics to Present at 15th Annual Pain Therapeutics Summit

San Diego, California--(Newsfile Corp. - October 26, 2021) - Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF) ("Tryp" or the "Company"), a pharmaceutical company focused on developing psilocybin-based compounds for diseases with unmet medical needs, today announced that the Company will present at the 15th Annual Pain Therapeutics Summit on November 1, 2021 at 12:15 p.m. EDT.

Oct 20, 2021 07:00 pm ET

Tryp Therapeutics Reports Clinical Hold on Proposed Phase 2a Study in Eating Disorders

San Diego, California--(Newsfile Corp. - October 20, 2021) - Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF) ("Tryp" or the "Company"), a pharmaceutical company focused on developing psilocybin-based compounds for diseases with unmet medical needs, today announced that the U.S. Food and Drug Administration ("FDA") has placed a clinical hold on the Company's Phase 2a study for eating disorders that includes binge eating disorder and hypothalamic obesity. The notification from the FDA did not provide a reason for the clinical hold and advised that the FDA would provide additional details any deficiencies within 30 days.

Oct 18, 2021 08:35 am ET

KCSA Psychedelics Virtual Investor Conference Presentations Available for On-Demand Viewing

NEW YORK, Oct. 18, 2021 /PRNewswire/ -- Virtual Investor Conferences in partnership with KCSA Strategic Communications today announced the presentations from the KCSA Psychedelics Virtual Investor Conference are now available for on-demand viewing.

Oct 18, 2021 08:35 am ET

KCSA Psychedelics Virtual Investor Conference Presentations Available for On-Demand Viewing

Individual and institutional investors as well as advisors are invited to log-on to VirtualInvestorConferences.com to view presentations

Oct 14, 2021 07:05 am ET

Tryp Therapeutics Announces Inclusion in AdvisorShares Psychedelics ETF

San Diego, California--(Newsfile Corp. - October 14, 2021) - Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF) ("Tryp"), a pharmaceutical company focused on developing psilocybin-based compounds for diseases with unmet medical needs, announced today its inclusion in the AdvisorShares Psychedelics ETF (the "Fund"), currently trading under the ticker symbol "PSIL" on the NYSE Arca exchange.

Oct 12, 2021 07:15 am ET

Tryp Therapeutics to Present at the KSCA Psychedelics Virtual Investor Conference

San Diego, California--(Newsfile Corp. - October 12, 2021) - Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF) ("Tryp" or the "Company"), a pharmaceutical company developing psilocybin-based compounds for diseases with unmet medical needs, announced today that it will present at the KCSA Psychedelics Virtual Investor Conference on October 14, 2021 at 3:00 p.m. EDT.

Oct 11, 2021 09:25 am ET

KCSA Psychedelics Virtual Investor Conference Agenda Announced for October 13th & 14th

Psychedelic and CNS Company Executives share vision, answer questions live at VirtualInvestorConferences.com

Oct 07, 2021 07:05 am ET

Tryp Therapeutics Announces Collaboration with Researchers at the University of Wisconsin-Madison

Tryp has partnered with Paul Hutson, PharmD and Christopher Nicholas, PhD to advance the Company's proprietary, psilocybin-based drug product

Sep 30, 2021 08:30 am ET

Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Leading Next Wave of Psychedelic Drug Development

NetworkNewsAudio – Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) announces the availability of a broadcast titled, “Investors Turning to Psychedelic Market as Renaissance Continues into New Wave of Diseases.” To hear the AudioPressRelease,...

Sep 28, 2021 08:30 am ET

Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Redefining Standards, Refining Psychiatry

via InvestorWire — Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) today announces its placement in an editorial published by NetworkNewsWire ("NNW"), one of 50+ trusted brands within the InvestorBrandNetwork (“IBN”), a multifaceted financial...

Sep 22, 2021 07:05 am ET

Tryp Therapeutics Submits IND Application for Phase 2a Clinical Trial in Eating Disorders

San Diego, California--(Newsfile Corp. - September 22, 2021) - Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF) ("Tryp"), a pharmaceutical company focused on developing psilocybin-based compounds for diseases with unmet medical needs, announced today that it has submitted an Investigational New Drug ("IND") application to the U.S. Food and Drug Administration ("FDA") to evaluate its clinical candidate, TRP-8802, in a Phase 2a study for the treatment of patients with eating disorders.

Sep 16, 2021 07:05 am ET

Tryp Therapeutics to Present at Oppenheimer Fall Healthcare Summit

San Diego, California--(Newsfile Corp. - September 16, 2021) - Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF) ("Tryp"), a pharmaceutical company focused on developing psilocybin-based compounds for diseases with unmet medical needs, announced today that it will present virtually at the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit.

Sep 01, 2021 10:01 am ET

CORRECTION FROM SOURCE: Tryp Therapeutics to Present at H.C. Wainwright Global Investment Conference

San Diego, California--(Newsfile Corp. - September 1, 2021) - Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF) ("Tryp"), a pharmaceutical company focused on developing psilocybin-based compounds for diseases with unmet medical needs through accelerated regulatory pathways, announced today that it will present at the H.C. Wainwright 23rd Annual Global Investment Conference.

Sep 01, 2021 07:05 am ET

Tryp Therapeutics to Present at H.C. Wainwright Annual Global Investment Conference

Aug 24, 2021 07:05 am ET

Tryp Therapeutics Completes Psychotherapy Training for Phase 2a Study at the University of Florida

The training, conducted by Fluence, represents a best-in-class approach for psychotherapy that will accompany the administration of psilocybin for overeating disorders

Aug 18, 2021 07:05 am ET

Tryp Therapeutics Appoints Dennis Langer, M.D., J.D. as Senior Advisor

San Diego, California--(Newsfile Corp. - August 18, 2021) - Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF) ("Tryp" or the "Company"), a pharmaceutical company focused on developing psilocybin-based compounds for diseases with unmet medical needs, announced today the appointment of Dennis Langer, M.D., J.D., as Senior Advisor to the Company.

Aug 10, 2021 07:05 am ET

Tryp Therapeutics Partners with Calvert Labs to Conduct Exploratory Studies for Proprietary Psilocybin Formulations

Tryp has also entered into an agreement with Gad Consulting Services to collaborate on the preclinical studies

Aug 03, 2021 08:00 am ET

InvestorBrandNetwork Announces The Dealmaker Show Interview with Tryp Therapeutics Inc. CEO Greg McKee

via InvestorWire – InvestorBrandNetwork (“IBN”), a multifaceted financial news and publishing company for private and public entities, today announces that Greg McKee, Chairman & CEO of Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF), a...

Aug 03, 2021 07:05 am ET

Tryp Therapeutics to Present at Canaccord Genuity Annual Growth Conference

San Diego, California--(Newsfile Corp. - August 3, 2021) - Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF) ("Tryp"), a pharmaceutical company focused on developing psilocybin-based compounds for diseases with unmet medical needs through accelerated regulatory pathways, announced today that it will present at the Canaccord Genuity Virtual Growth Conference.

Jul 30, 2021 08:30 am ET

Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Exploring Psilocybin Treatments in Underserved Indications

NetworkNewsAudio – Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) announces the availability of a broadcast titled, “Psychedelics — Not Just for Mental Health Anymore.” To hear the AudioPressRelease, please visit: The NetworkNewsAudio News...

Jul 28, 2021 11:19 pm ET

Tryp Therapeutics Announces Q3 2021 Financial Results

San Diego, California--(Newsfile Corp. - July 28, 2021) - Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF) ("Tryp" or the "Company"), a pharmaceutical company focused on developing psilocybin-based compounds for diseases with unmet medical needs through accelerated regulatory pathways, announced today its interim financial results for the three and nine month period ended May 31, 2021. Complete financial statements along with related management discussion and analysis can be found in the System for Electronic Document Analysis and Retrieval, the electronic filing system for the disclosure documents of issuers across Canada, at www.SEDAR.com.

Jul 28, 2021 08:30 am ET

Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Developing Evidence-Based Innovation Where Drugs Are Lacking

Jul 26, 2021 09:43 am ET

Tryp Therapeutics Appoints Robin Carhart-Harris, Ph.D. as SAB Chairman and Adds Daniel Clauw, M.D. as Scientific Advisor

San Diego, California--(Newsfile Corp. - July 26, 2021) - Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF) ("Tryp"), a pharmaceutical company focused on developing psilocybin-based compounds for diseases with unmet medical needs through accelerated regulatory pathways, announced today the appointment of Robin Carhart-Harris, Ph.D. as Chairman of its Scientific Advisory Board ("SAB") and Daniel Clauw, M.D. as a new member of the SAB.

Jul 21, 2021 07:00 am ET

Tryp Therapeutics Announces Plans for Phase 2a Clinical Trial for Fibromyalgia with the University of Michigan

The study is expected to be the world's first Phase 2a clinical trial evaluating the efficacy of psilocybin and psychotherapy to treat fibromyalgia

Jul 15, 2021 07:00 am ET

Tryp Therapeutics to Host Q3 Investor Day on July 29, 2021

San Diego, California--(Newsfile Corp. - July 15, 2021) - Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF) ("Tryp"), a pharmaceutical company focused on developing psilocybin-based compounds for diseases with unmet medical needs through accelerated regulatory pathways, announced today that it will host their Q3 Investor Day on July 29, 2021 at 9:00 a.m. PDT.

Jul 07, 2021 07:00 am ET

Tryp Therapeutics Partners with the University of Michigan to Evaluate Proprietary Formulations

Tryp has also entered into an advisory agreement with George Mashour, M.D., Ph.D., who serves as Chair of the Department of Anesthesiology at the University of Michigan Medical School

Jul 01, 2021 08:30 am ET

Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Differentiated by Clinical Trials, World-Class Management

NetworkNewsAudio – Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) announces the availability of a broadcast titled, “GW Pharma Sells for Bilions; Psychedelic Company Following Similar Path.” To hear the AudioPressRelease, please visit: The...

Jun 30, 2021 08:30 am ET

Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Charting Its Own Course in Psychedelic Space

Jun 24, 2021 07:00 am ET

Tryp Therapeutics to Present at the Psych Investor Summit

San Diego, California--(Newsfile Corp. - June 24, 2021) - Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF) (FSE: 8FW) ("Tryp"), a pharmaceutical company focused on developing compounds for diseases with unmet medical needs through accelerated regulatory pathways, announced today that it is presenting at the Psych Investor Summit: Research & Development. The conference will be held virtually on July 7. Greg McKee, Chairman and CEO, will present information on the company and its drug development pipeline in addition to contributing to a panel discussion on the future of research and development activities for psychedelic drug compounds.

Jun 17, 2021 08:17 am ET

InvestorBrandNetwork (IBN) Announces Latest Episode of Stock2Me Podcast featuring Tryp Therapeutics Inc. Chairman and CEO Greg McKee

(via InvestorWire) InvestorBrandNetwork (“IBN”), a multifaceted communications organization engaged in connecting public companies to the investment community, is pleased to announce the release of the latest episode of The Stock2Me Podcast as part...

Jun 08, 2021 07:00 am ET

Tryp Therapeutics to Present at the Ladenburg Thalmann Healthcare Conference

San Diego, California--(Newsfile Corp. - June 8, 2021) - Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF) (FSE: 8FW) ("Tryp"), a pharmaceutical company focused on developing compounds for diseases with unmet medical needs through accelerated regulatory pathways, announced today that it is presenting at the Ladenburg Thalmann Healthcare Conference. The conference will be held virtually on July 13 and 14. Greg McKee, Chairman and CEO; Jim Gilligan, President and Chief Science Officer; and Luke Hayes, CFO, will provide an overview of Tryp's business and its pipeline followed by a brief analyst-led fireside chat.

Jun 01, 2021 10:41 pm ET

Tryp Therapeutics to Present at the H.C. Wainwright Psychedelics Conference

San Diego, California--(Newsfile Corp. - June 1, 2021) - Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF) (FSE: 8FW) ("Tryp"), a pharmaceutical company focused on developing compounds for diseases with unmet medical needs through accelerated regulatory pathways, announced today that it is presenting at the "Psychedelics in Psychiatry and Beyond" conference sponsored by H.C. Wainwright & Co. The conference will be held virtually on June 17, 2021. Greg McKee, Chairman and CEO of Tryp, will provide an overview of the business and its pipeline including Tryp's Psilocybin-For-Neuropsychiatric Disorders (PFNTM) program for chronic pain and eating disorder indications.

May 25, 2021 04:00 am ET

Tryp Therapeutics Partners with Alcami for Proprietary Formulations

The agreement represents another step toward the proprietary manufacturing, formulation, and delivery of products for Tryp's Psilocybin-For-Neuropsychiatric Disorder (PFN(TM)) program

May 21, 2021 08:30 am ET

Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Brings Best-in-Class Team to Psychedelics Development

NetworkNewsAudio – Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) announces the availability of a broadcast titled, “Wall Street Unicorns in Process of Changing the Healthcare Landscape.” To hear the AudioPressRelease, please visit: The...

May 19, 2021 08:30 am ET

Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Bringing Diversified Pipeline to Psychedelic Revival

May 10, 2021 04:00 am ET

Tryp Therapeutics Partners with Clinlogix for Clinical Trial Support

The agreement with Clinlogix is a key step for initiating Tryp's Phase 2a clinical trials

May 03, 2021 04:00 am ET

Tryp Therapeutics Partners with Fluence for Psychotherapy Design

The partnership with Fluence expands Tryp's ability to conduct comprehensive clinical trials and leverage invaluable experience and insight from the leader in psychedelic therapy training

Apr 29, 2021 09:05 am ET

Tryp Therapeutics Announces Q2 2021 Financial Results

San Diego, California--(Newsfile Corp. - April 29, 2021) - Tryp Therapeutics Inc. (CSE: TRYP) ("Tryp" or the "Company"), today announced its interim financial results for the three and six month periods ended February 28, 2021. Complete financial statements along with related management discussion and analysis can be found in the System for Electronic Document Analysis and Retrieval, the electronic filing system for the disclosure documents of issuers across Canada at www.SEDAR.com.

Apr 20, 2021 07:00 am ET

Tryp Therapeutics Reports on Key Milestones for 2021

San Diego, California--(Newsfile Corp. - April 20, 2021) - Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) ("Tryp" or the "Company"), a pharmaceutical company focused on developing clinical-stage compounds for diseases with unmet medical needs, reported today on the Company's significant progress since successfully completing its Initial Public Offering in December 2020.

Apr 15, 2021 07:00 am ET

Tryp Therapeutics to Host Investor Day on April 22

San Diego, California--(Newsfile Corp. - April 15, 2021) - Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) ("Tryp" or the "Company"), a pharmaceutical company focused on developing clinical-stage compounds for diseases with unmet medical needs, is pleased to announce that it will be hosting its quarterly Investor Day on Thursday, April 22 at 9:00 a.m. PDT.

Apr 05, 2021 12:38 pm ET

Tryp Therapeutics Announces Listing on OTCQB and DTC Eligibility

San Diego, California--(Newsfile Corp. - April 5, 2021) - Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF) ("Tryp" or the "Company") a pharmaceutical company focused on developing clinical-stage compounds for diseases with unmet medical needs, announced today it has initiated quoting activity on the OTCQB® Venture Market (the "OTCQB") and is eligible for settlement and transfer of its common shares in the United States with The Depository Trust Company ("DTC").

Apr 01, 2021 09:48 pm ET

Tryp Therapeutics Announces Amendment to Option Plan and Option Grant

San Diego, California--(Newsfile Corp. - April 1, 2021) - Tryp Therapeutics Inc. (CSE: TRYP) ("Tryp" or the "Company"), a pharmaceutical company focused on developing clinical-stage compounds for diseases with unmet medical needs, is pleased to announce that it has amended the terms of its stock option plan (the "Plan") and granted stock options (the "Options") to a director of the Company.

Apr 01, 2021 07:00 am ET

Tryp Therapeutics Appoints Greg McKee as Chief Executive Officer

San Diego, California--(Newsfile Corp. - April 1, 2021) - Tryp Therapeutics Inc. (CSE: TRYP) ("Tryp" or the "Company"), a pharmaceutical company focused on developing clinical-stage compounds for diseases with unmet medical needs, is pleased to announce that it has appointed Greg McKee as its Chief Executive Officer. Mr. McKee will also continue in his responsibilities as Chairman of the Board of Directors of the Company.

Mar 18, 2021 05:00 am ET

Tryp Therapeutics Announces Provisional Patent Filing For Improved Administration of Psychedelics

La Jolla, California--(Newsfile Corp. - March 18, 2021) - Tryp Therapeutics (CSE: TRYP), a pharmaceutical company focused on developing clinical-stage compounds for diseases with unmet medical needs, announced today that it has submitted a provisional patent (US 63/161,070) to improve how psychedelics are administered across a broad range of indications.

Mar 09, 2021 08:53 pm ET

Tryp Therapeutics Appoints Luke Hayes as Chief Financial Officer

La Jolla, California--(Newsfile Corp. - March 9, 2021) - Tryp Therapeutics Inc. (CSE: TRYP) ("Tryp" or the "Company"), a pharmaceutical company focused on identifying and developing clinical-stage compounds for diseases with high unmet medical needs, is pleased to announce that it has appointed Luke Hayes as its Chief Financial Officer.

Mar 04, 2021 10:00 am ET

Tryp Therapeutics Announces Application to List on OTCQB

La Jolla, California--(Newsfile Corp. - March 4, 2021) - Tryp Therapeutics (CSE: TRYP) ("Tryp" or the "Company") a pharmaceutical company focused on identifying and developing clinical-stage compounds for diseases with high unmet medical needs, announced today that it has submitted its application for a listing to the OTCQB® Venture Market ("OTCQB").

Feb 24, 2021 07:00 am ET

Tryp Therapeutics to Present at the Stifel GMP Healthcare Conference

La Jolla, California--(Newsfile Corp. - February 24, 2021) - Tryp Therapeutics (CSE: TRYP) ("Tryp" or the "Company") a pharmaceutical company focused on identifying and developing clinical-stage compounds for diseases with high unmet medical needs, announced today the company has been invited to present at the Stifel GMP Healthcare Conference: Healthcare Psychedelics: Addressing the Global Mental Health Crisis.

Feb 17, 2021 05:38 pm ET

Tryp Therapeutics Completes $2 Million Strategic Financing

La Jolla, California--(Newsfile Corp. - February 17, 2021) - Tryp Therapeutics Inc. (CSE: TRYP) ("Tryp"), a pharmaceutical company focused on identifying and developing clinical-stage compounds for diseases with high unmet medical needs, is pleased to announce that effective February 16, 2021, it has closed its previously announced financing (see news release February 5, 2021) and issued 3,333,333 million units (the "Units") at a price of $0.60 per Unit, for proceeds of $2 million (the "Placement").

Feb 16, 2021 12:10 am ET

Tryp Therapeutics Reaches Milestone on Psilocybin Drug Manufacturing Program

La Jolla, California--(Newsfile Corp. - February 16, 2021) - Tryp Therapeutics (CSE: TRYP) ("Tryp" or the "Company") a pharmaceutical company focused on identifying and developing clinical-stage compounds for diseases with high unmet medical needs, announced that Albany Molecular Research ("AMRI") has begun the process of manufacturing the 200g non-GMP demonstration batch of psilocybin. This production step is one of a series of steps in the project plan to manufacture batches of Tryp's proprietary formulation of cGMP psilocybin to support the company's clinical development and for the company's upcoming clinical trials.

Feb 11, 2021 03:30 am ET

Tryp Therapeutics Appoints Dr. Joel Castellanos as Clinical Advisor

La Jolla, California--(Newsfile Corp. - February 11, 2021) - Tryp Therapeutics (CSE: TRYP) ("Tryp" or the "Company") a pharmaceutical company focused on identifying and developing clinical-stage compounds for diseases with high unmet medical needs, announced today it has executed an advisory agreement with Dr. Joel Castellanos, a noted chronic pain physician at UC San Diego Medical Center to join the company's Scientific Advisory Board. He will guide Tryp's clinical development of TRP-8802 for neuropathic pain indications. Dr. Castellanos is the lead author of, "Chronic pain and psychedelics: a review and proposed mechanism of action", which was published online in Regional Anesthesia & Pain Medicine on May 4, 2020.

Feb 08, 2021 06:42 pm ET

Tryp Therapeutics Plans Phase 2a Eating Disorder Clinical Trial with Dr. Jennifer Miller

La Jolla, California--(Newsfile Corp. - February 8, 2021) - Tryp Therapeutics (CSE: TRYP) ("Tryp"), a leading pharmaceutical company focused on identifying and developing clinical-stage compounds for diseases with high unmet medical needs, announces it has commenced a collaboration with Dr. Jennifer Miller of the University of Florida as the Principal Investigator for a clinical trial to treat the symptoms associated with eating disorders. Tryp and Dr. Miller have begun designing a Phase 2a open-label, exploratory clinical study utilizing TRP-8802 in patients suffering from rare and orphan over-eating disorders.

Feb 05, 2021 03:10 am ET

Tryp Therapeutics Announces Strategic Investment of $2,000,000

La Jolla, California--(Newsfile Corp. - February 5, 2021) - Tryp Therapeutics Inc. (CSE: TRYP) ("Tryp") is pleased to announce a non-brokered private placement (the "Placement") of 3,333,333 million units (the "Units") at a price of $0.60 per Unit, to raise gross proceeds of approximately $2.0 million. Marc Lustig, founder and former Chairman of Origin House has committed to be a lead participant in the Placement.

Feb 03, 2021 04:00 am ET

Tryp Therapeutics Announces Appointment of Greg McKee as Executive Chairman

La Jolla, California--(Newsfile Corp. - February 3, 2021) - Tryp Therapeutics (CSE: TRYP) ("Tryp"), a leading pharmaceutical company focused on identifying and developing clinical-stage compounds for diseases with high unmet medical needs, needs is pleased to announce the appointment of Greg McKee as Executive Chairman.

Feb 02, 2021 03:01 am ET

Tryp Therapeutics Appoints Dr. Robin Carhart-Harris to Scientific Advisory Board

La Jolla, California--(Newsfile Corp. - February 2, 2021) - Tryp Therapeutics, a clinical-stage pharmaceutical company developing medications targeting diseases with high unmet medical needs, is pleased to announce that it has added world renowned psychedelic scientist, Dr. Robin Carhart Harris to help lead its Scientific Advisory Board.

Jan 19, 2021 07:00 am ET

Tryp Therapeutics Invited to Present at "Investing in Psychedelics" Conference

La Jolla, California--(Newsfile Corp. - January 19, 2021) - Tryp Therapeutics (CSE: TRYP), a leading pharmaceutical company focused on identifying and developing clinical-stage compounds for diseases with high unmet medical needs, has been invited to present at the upcoming Investing in Psychedelics Conference hosted by The CSE (Canadian Securities Exchange).

Jan 14, 2021 07:00 am ET

Tryp Therapeutics Strengthens Board of Directors with Appointment of Gregory M. McKee

La Jolla, California--(Newsfile Corp. - January 14, 2021) - Tryp Therapeutics Inc. (CSE: TRYP) ("Tryp" or the "Company"), a pharmaceutical company focused on identifying and developing clinical-stage compounds for diseases with high unmet medical needs, is pleased to announce the appointment of Gregory M. McKee to the Company's board of directors.

Jan 13, 2021 07:00 am ET

Tryp Therapeutics Invited to Present at Global Healthcare & Psychedelic Conferences

La Jolla, California--(Newsfile Corp. - January 13, 2021) - Tryp Therapeutics, a leading pharmaceutical company focused on identifying and developing clinical-stage compounds for diseases with high unmet medical needs, announced today it has been invited to present at two upcoming industry conferences in January and February 2021.

Jan 07, 2021 07:00 am ET

Tryp Therapeutics Appoints Dr. William K. Schmidt to Its Scientific Advisory Board

La Jolla, California--(Newsfile Corp. - January 7, 2021) - Tryp Therapeutics (CSE: TRYP) ("Tryp" or the "Company") a pharmaceutical company focused on identifying and developing clinical-stage compounds for diseases with high unmet medical needs, announced today it has appointed Dr. William K. Schmidt, a noted authority in the development of pain drugs, as a Scientific Advisory Board member. Dr. Schmidt, will aid Tryp in the development of its product candidate TRP-8802 for fibromyalgia and other chronic pain conditions.

Dec 23, 2020 03:39 pm ET

Tryp Therapeutics Announces Grant of Stock Options

LA JOLLA, Calif., Dec. 23, 2020 /CNW/ - Tryp Therapeutics Inc. ("Tryp" or the "Company") (CSE: TRYP) announces the grant of 400,000 stock option (the "Options") to certain directors of the Company. The Options have an exercise price of $0.75 per share, are exercisable until December 22, 2030 and will be governed in accordance with the terms of the Company's stock option plan.

Dec 22, 2020 07:00 am ET

Tryp Therapeutics Appoints Peter Guzzo, PhD, as Vice President, Drug Development

La Jolla, California--(Newsfile Corp. - December 22, 2020) - Tryp Therapeutics Inc. (CSE: TRYP) ("Tryp" or the "Company") a pharmaceutical company focused on identifying and developing compounds for diseases with high unmet medical needs, announced today it has appointed Dr. Peter Guzzo as its Vice President of Drug Development.

Dec 18, 2020 07:00 am ET

Tryp Therapeutics Begins Trading on the Canadian Securities Exchange

La Jolla, California--(Newsfile Corp. - December 18, 2020) - Tryp Therapeutics Inc. (CSE: TRYP) ("Tryp" or the "Company") is pleased to announce that the Company's common shares have commenced trading on the Canadian Securities Exchange ("CSE") under the symbol "TRYP" effective December 18, 2020.

Dec 17, 2020 11:41 am ET

Tryp Therapeutics Completes Initial Public Offering

La Jolla, California--(Newsfile Corp. - December 17, 2020) - Tryp Therapeutics Inc. ("Tryp" or the "Company") is pleased to announce the successful closing of previously announced initial public offering (the "Offering") of units (the "Units"). A total of 20,010,000 Units were sold, including 2,610,000 Units following the exercise in full by the Agent (as defined herein) of its over-allotment option, at a price of $0.25 per Unit for aggregate gross proceeds of $5,002,500.

Ad blocking detected

TRYP Therapeutics Inc. (C:TRYP)

Business Focus: Biotechnology & Medical Research (NEC)